IONIS PHARMACEUTICALS INC (IONS)
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
📈 **POSITIVE** • Medium confidence analysis (77%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business